Health News Highlights: Vaccines, Drug Developments And Policy Changes

Coverage of the current health news ranges from the struggles of Africa with mpox to the forecasted sales of Moderna vaccines. Other highlights include Fulcrum's stock drop due to failed trials, Avadel's sleep drug review, F2G's significant fundraiser, and Eli Lilly's major investments. India's expanded health coverage plan is also notable.

Current health news addresses issues from vaccine distribution to pharmaceutical developments and policy changes.

Rich nations hold millions of mpox vaccine doses as Africa struggles with an outbreak, while Moderna forecasts sales between $2.5 billion and $3.5 billion for next year despite a dip in revenue.

Fulcrum's experimental drug failure causes its stock to plummet, and Avadel's sleep disorder treatment remains under FDA review. Meanwhile, F2G raises $100 million to combat 'superbugs', and Eli Lilly invests $1.8 billion in Irish facilities to enhance Alzheimer's and obesity drug production.

In other updates, Bavarian Nordic plans to ramp up its mpox vaccine capacity, GSK's mRNA flu vaccine moves to late-stage trials, and Roche shares drop amid concerns over its weight-loss pill. Additionally, India expands health coverage for citizens over 70, significantly impacting 60 million more people.

(With inputs from agencies.)